About the Webinar

Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder driven by the BCR-ABL fusion gene, which produces an abnormal tyrosine kinase. The introduction of tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib has revolutionized CML treatment, transforming it into a manageable chronic condition. Effective management requires regular molecular monitoring using quantitative PCR to assess BCR-ABL transcript levels and guide therapy adjustments. Resistance mutations, adherence issues, and side effects must be carefully addressed. Ongoing research into newer TKIs and treatment-free remission strategies continues to improve long-term outcomes and quality of life for patients with CML.

Meet the Speaker

Dr. Ram Ganjoo

Senior Consultant Medicine & Clinical Haematology, Sarvodaya Medicentre, Delhi

Dr. Ram Ganjoo is a Senior Consultant in Medicine and Clinical Haematology at Sarvodaya Medicentre, Delhi. With extensive experience in managing complex hematological and internal medicine cases, he is known for his patient-centered and evidence-based approach to care. Dr. Ganjoo has a special interest in diagnosing and treating blood disorders, including anemia, leukemia, and clotting abnormalities. His commitment to excellence and continuous learning has earned him respect among peers and trust among his patients.